SLC5A2 and Hyperkalemia: Notably, co-administration of MRAs and SGLT-2 inhibitors has been shown to reduce the risk of hyperkalaemia while offering additional therapeutic benefits for patients with heart failure or type 2 diabetic nephropathy (Provenzano et al., 2022).